A systematic review protocol examining the effect of vitamin D supplementation on endothelial function by Alyami, A. et al.
A systematic review protocol examining
the effect of vitamin D supplementation
on endothelial function
A Alyami,1 MJ Soares,1 JL Sherriff,1 Y Zhao,2 J Hallett,3 F Coombes4
To cite: Alyami A, Soares MJ,
Sherriff JL, et al. A
systematic review protocol
examining the effect of
vitamin D supplementation




▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006835).
Received 6 October 2014
Revised 1 May 2015
Accepted 7 May 2015
1Directorate of Nutrition,
Dietetics & Food Technology,
School of Public Health,
Curtin Health Innovation
Research Institute of Ageing









Research and Impact in
Public Health, School











Introduction: Vitamin D has potential benefits for
extraskeletal health. These could include an anti-
inflammatory effect as well as a reduction in endothelial
dysfunction. We aim to provide quality evidence for the
hypothesis that supplementation with vitamin D will
improve endothelial function (EF), possibly through the
abrogation of systemic inflammation.
Methods and analysis: We will conduct a systematic
review of all randomised controlled trials on vitamin D
supplementation and EF lasting 12 weeks or more. The
search will cover the period 2000–2015 and include
studies that describe direct measures of EF, markers of
endothelial cell (EC) activation and if concurrently
reported, indicators of systemic inflammation. Study
selection will follow the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines and study quality will be assessed by the
Jadad score in addition to an evaluation of allocation
concealment and data analysis. If sufficient data are
available, a meta-analysis will be conducted. The effect
sizes will be generated using Hedges’ g score, for both
fixed and random effect models. I2 statistics and
Galbraith plots will be used to assess heterogeneity and
identify their potential sources. Potential publication and
small sample size bias will be assessed by visual
inspections of funnel plots and also Egger’s test.
Meta-regression analysis (if feasible) will be conducted
with restricted maximum likelihood (REML) estimation
method, controlling for potential confounders
(demographics, study methods, location, etc). A
backward elimination process will be applied in the
regression modelling procedure. Subgroup analysis,
conditional on number of studies retrieved and their
sample size, will be stratified on participant disease
category, total dose administered, degree of 25(OH)D
change and type of supplement used.
Ethics and dissemination: Formal ethical approval is
not required as primary data will not be collected. The
results will be disseminated through a peer-reviewed
publication, conference presentation and the popular
press.
Trial registration number: International Prospective
Register for Systematic Reviews (PROSPERO) number
CRD42014013523.
INTRODUCTION
The vascular endothelium plays a pivotal
role in the detection and response to
blood-borne signals and changes in haemo-
dynamic forces. Endothelial dysfunction is
strongly linked to cardiovascular disease
(CVD),1 and can predict the occurrence of
type 2 diabetes (T2DM).2 A chronic low-
grade inflammation is common to many
metabolic disorders,3 and also underscores
endothelial dysfunction.4 5 Vitamin D inad-
equacy is now a global issue and normalisa-
tion of status has a potential protective role
in conditions such as obesity, CVD and
T2DM.6–11 Vitamin D status is related to
inflammation.12 13 The conversion of 25
(OH)D to its active form 1,25(OH)2D occurs
in immune system cells such as dendritic
cells, macrophages, T cells and B cells.14 The
outcome of 1,25(OH)2D action in these cells
is a decreased production of interferon γ
(INF-γ), interleukin-12 (IL-12), interleukin-6
(IL-6), and interleukin-23(IL-23) with an
enhanced production of IL-4.14 Vitamin D
may also benefit endothelial function
(EF).15 16 The endothelium can convert 25
(OH)D to its active form through a specific
endothelial 1 α-hydroxylase.17 Interestingly,
greater enzyme activity is stimulated by
inflammatory cytokines.18 Protective effects
of vitamin D may then be realised through
Strengths and limitations of this study
▪ Systematic review and meta-analysis of rando-
mised controlled trials.
▪ Will offer highest level of evidence for informed
decisions.
▪ Potential clarification that the effect of vitamin D
status on endothelial dysfunction is through
inflammation.
▪ Availability of quality studies with direct mea-
sures of endothelial function based on the same
technique.
▪ The many inflammatory and endothelial activa-
tion biomarkers in the literature hamper collation
of outcomes.
▪ Key words: endothelial function, vitamin D,
inflammation, systematic review, randomised
controlled trials.
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increased nitric oxide (NO) production, decreased oxi-
dative stress, reduced IL-6, vascular cell adhesion mole-
cules (VCAM) and intracellular adhesion molecule
(ICAM) among other effects.16 Thus the overall impact
of adequate vitamin D in this context would be to
decrease both systemic inflammation and endothelial
dysfunction.
One of the most important actions of endothelium is
the production of NO, which plays a major role in regu-
lating the vessel diameter and, hence resistance, through-
out the arterial bed.19 However, two other endothelial
cell (EC) products, endothelium-derived hyperpolarising
factor and prostacyclin (PGI2), also produce vasodilation
of the underlying smooth muscle cells, and overall these
actions are countered by the vasoconstrictor EC factor
endothelin-1 in the regulation of vascular tone.15
Endothelial dysfunction is characterised by reduced
NO-dependent vascular activity which leads to dysregula-
tion of arterial tone.20 However, there is an endothelium
independent pathway as well that is determined by the
activity of the smooth muscle layer. Sublingual glyceryl tri-
nitrate (GTN) can be used to uncover the influence of
this pathway,21 as GTN decreases smooth muscle tone
leading to vasodilation.21 A comprehensive assessment of
EF usually encompasses the testing of both pathways.
EF is assessed by testing the vascular reactivity of
either coronary or peripheral arteries. Initially the
invasive technique of artery catheterisation was used;
this assesses endothelial-dependent vasodilation.
Subsequently, non-invasive techniques like flow-mediated
dilation (FMD) were developed. This is the current gold
standard for measuring EF in peripheral arteries. FMD
uses ultrasound imaging to detect the endothelial
response to shear stress, acetylcholine infusion, and sal-
butamol inhalation for the assessment of the
endothelial-dependent pathway, or sublingual GTN for
the endothelial-independent pathway. More recently,
pulse contour analysis (PCA), based on a photoplethys-
mographic recording of the digital volume pulse, has
been used to assess EF.22 The derived variables, stiffness
index and reflective index (RI) reflect large artery stiff-
ness and small artery vascular tone, respectively.23
Studies that employ both salbutamol and GTN in con-
junction with PCA have been used to report endothelial
dysfunction. On the other hand, arterial applanation
tonometry uses a sensitive probe applied in turn to the
carotid and femoral arteries to detect characteristics of
the transmitted waveform. A derived variable is the aug-
mentation index (AIx), the ratio of the pulse pressure at
the second systolic peak to the pulse pressure of the first
systolic peak.24 Other studies have also employed
markers of EC activation, like higher plasma levels of
soluble VCAM, ICAM, P-selectin and E-selectin as indica-
tors of endothelial dysfunction.15 Systemic inflammation
is usually measured by the levels of circulating inflamma-
tory biomarkers such as high sensitivity C reactive
protein (CRP), white cell count (WCC), INF- γ, IL-12,
IL-6, IL-23 and IL-4.14 25 CRP is an interesting marker
since its effect on EC activation5 could underscore its
high prediction of CVD.5 25 Moreover, strong relation-
ships between WCC, ICAM and fibrinogen and the pre-
diction of CVD has also been documented.1 26
Collectively, there is sufficient evidence to hypothesise
that adequate vitamin D status may directly attenuate
endothelial dysfunction (as supported from functional
measures and/or markers of EC activation), or act indir-
ectly through the abrogation of systemic inflammation.
Two limited narrative reviews on randomised controlled
trials (RCTs) did not, however, uncover consistent
support for an effect of vitamin D on improvements in
EF or decreases in markers of EC activation.15 16 Clearly
there is a need to expand the scope of such findings to
arrive at an evidence-based conclusion. To our knowl-
edge there is no published systematic review that
addresses our question. Previous systematic reviews in
related fields have examined the links between vitamin
D and CRP,27 and vitamin D and blood pressure,28 while
a narrative review reported on vitamin D, blood pres-
sure, endothelial and renal function of postmenopausal
women.29 The present systematic review protocol will
evaluate potential causal interrelationships between
vitamin D status and EF, and determine whether systemic
inflammation is a moderator of the effect. We address
our objectives through a comprehensive protocol target-
ing all RCTs in this area, from 2000 to 2015, in order to
confirm or negate this extraskeletal role for vitamin D.
METHODS AND DESIGN
Population
The systematic review will include high quality RCTs on
adults aged >20 years who have been supplemented with
cholecalciferol or calcitriol, and have had measures of
EF, EC activation and/or systemic inflammation before
and after the interventions. The study population will be
restricted to healthy subjects, and overweight or obese
who suffer from glucose intolerance, CVD, metabolic
syndrome (MetS) or T2DM.
Study design
This systematic review will consider only randomised
controlled trials of good quality.
Search strategy
The search strategy aims to find published articles only,
and will include a three-stage protocol (figure 1). An
initial limited search of Medline and Scopus will be
undertaken; this will be followed by analysis of the text
words contained in the titles and abstracts, and of the
index terms used to describe each article. A second
search, using all identified keywords and index terms,
will then be undertaken across all included databases. In
the third step, the reference lists of key articles will be
searched for additional studies. Studies will be restricted
to the English language and to those published from
2000 to 2015, inclusive. The databases that will be
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searched are Medline, Science Direct, Scopus, Web of
Science, Cochrane Library of Systematic Reviews,
ProQuest, Wiley and Highwire Press.
Study selection
Quantitative studies will be independently assessed by
three reviewers and reported using the PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) flow diagram.30 Valid studies will then be
assessed for their quality before any retrieval of informa-
tion. Any disagreements that arise between the reviewers
will be resolved through discussion.
Quality assessment
The three reviewers will independently check each
selected article to minimise bias. All selected articles will
be judged for their quality based on the Jadad score31 in
addition to an evaluation of allocation concealment and
data analysis.32
Data extraction
Quantitative data will be extracted from papers receiving a
Jadad score of 3 and over with adequate allocation con-
cealment and proper data analysis.31 32 The data extracted
will include all details specific to the review question and
fulfils the requirements for both the narrative synthesis of
outcomes and the potential meta-analysis. We will also
contact corresponding authors for key information when
data are ambiguous or missing from the published study.
Data extraction will be independently cross-checked.
Outcomes
The outcomes of the review will be grouped under the
following headings
▸ EF: this will include direct measures as measured by
flow mediated dilation (FMD), PCA, AIx or endothe-
lial vasodilation/vasoconstriction following drug
intervention.
▸ EC activation: these include circulating markers such
as P-selectin, E-selectin, L-selectin, VCAM-1, ICAM-1
or von Willebrand factor.
▸ Systemic inflammatory molecules: these will include
markers, such as nuclear factor κ-light-chain-
enhancer of activated B cells (NF-KB), pro-
inflammatory cytokine IL-6, IL-12, and high-sensitivity
CRP, as well as anti-inflammatory cytokines such as
IL-6, IL-10, and adiponectin.
ANALYSIS
Descriptive analysis
A narrative synthesis of the outcomes of the selected
studies will be presented in the final review. This will
include the following:
1. Type of intervention and the control group and
sample size;
2. 25(OH)D3 baseline and final measurement and
other biomarkers of interest;
3. Targeted population and its characteristics; age, sex,
ethnicity, disease prevalence in group, location and
the distance from equator, if possible;
4. Intervention outcomes: this will include the change in
25(OH)D, measurements of EF such as FMD, AIx and
PCA derived end points RI and stiffness index, sys-
temic inflammatory biomarkers, EC activation biomar-
kers, time between last dose and EF measurement.
Statistical analysis
We are interested in the relationship between vitamin D
supplementation and endothelial dysfunction. Endothelial
dysfunction is measured in different ways among studies;
therefore, we anticipate a limited ability to run a
meta-analysis for this review. However, in studies which
used the same end point measurements we will report pre-
intervention, postintervention and overall mean change
pertaining to the endothelial dysfunction outcomes of
interest. The overall mean change will be calculated by
subtracting the mean change in the placebo group from
that in the treatment group in the studies if these had a
parallel design. Standard deviation (SD) will be calculated
from standard errors (SEs), or confidence interval
(95% CI), or t or F value from raw data, where available,
for both the placebo group and the treatment group for
each study included.
Meta-analysis (where possible) will be carried out to
assess the effect of vitamin D supplementation on
Figure 1 A schematic of the proceses of the systemic
review. (Randomised controlled trials (RCTs); Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)).
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measures of EF and systemic/vascular inflammation.
Effectiveness of vitamin D supplementation on endothe-
lial dysfunction will be reported as standardised mean
difference (SMD) for each individual study and its
95% CI. A positive SMD will denote a higher (more
favourable) value in the vitamin D3 group. The effect
sizes will be generated using Hedges’ g score and pre-
sented using a forest plot for each study to assess the
magnitude of the intervention effect on a particular
outcome. The overall effect sizes will be estimated using
both fixed-effects models and random-effects models. I2
statistics and Galbraith plot will be used to assess for het-
erogeneity and identify the potential sources of hetero-
geneity. Subgroup analyses, conditional on number of
studies retrieved and their sample size, will be stratified
on participant disease category (eg, CVD/MetS/T2DM)
or total dose administered (daily dose × duration)
(low-medium-high) or degree of 25(OH)D change
(low-medium-high) or supplement used (calcitriol vs
vitamin D3 alone vs calcium + vitamin D3).
Potential publication and small sample size bias will be
assessed by visual inspections of funnel plots and also
Egger’s test. To explore the effect of main factors of inter-
est on predicting SMD, meta-regression analysis will be
conducted with restricted maximum likelihood (REML)
estimation method, controlling for potential confounders
(demographics, study methods, and location). Backward
elimination process will be applied in the regression
modelling procedure. All of the statistical analysis will be
performed by using STATA V.12.0 (StataCorp, College
Station, Texas, USA).33 A p value<0.05 will be considered
statistically significant for all analyses.
CONCLUSION
This systematic review will provide evidence in support
or against the hypothesis that vitamin D has a role in
EF. This conclusion will stem from direct measure-
ments of EF and/or EC activation, and indirectly
through changes in biomarkers of systemic inflamma-
tion. Where sufficient data are available, we will
conduct a meta-analysis to confirm the relationship
between the improvement in vitamin D status and the
reduction in endothelial dysfunction. Moreover,
whether this occurs through a reduction in systemic
inflammation will also be clarified. Overall, the review
will complement the evidence base on the extraskele-
tal benefits of vitamin D.
Acknowledgements The authors thank the reviewers of the manuscript for
their constructive feedback.
Contributors AA, MJS, JLS and JH conceived the idea, planned and designed
the study protocol. AA designed the figure and wrote the first draft; YZ
planned the data extraction and statistical analysis; FC provided critical
insights. All authors have approved and contributed to the final written
manuscript.
Funding This study was supported by intramural funds from School of Public
Health, Curtin University. AA is recipient of a PhD scholarship from the Saudi
Ministry of Health.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of
inflammation and cardiovascular disease application to clinical and
public health practice: a statement for healthcare professionals from
the centers for disease control and prevention and the American
Heart Association. Circulation 2003;107:499–511.
2. Meigs JB, Hu FB, Rifai N, et al. Biomarkers of endothelial dysfunction
and risk of type 2 diabetes mellitus. JAMA 2004;291:1978–86.
3. Hotamisligil GS. Inflammation and metabolic disorders. Nature
2006;444:860–7.
4. Huang AL, Vita JA. Effects of systemic inflammation on endothelium-
dependent vasodilation. Trends Cardiovasc Med 2006;16:15–20.
5. Szmitko PE, Wang CH, Weisel RD, et al. New markers of
inflammation and endothelial cell activation part I. Circulation
2003;108:1917–23.
6. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with
health consequences. Amer J Clin Nutr 2008;87:1080S–6S.
7. Peterlik M, Cross H. Vitamin D and calcium insufficiency-related
chronic diseases: molecular and cellular pathophysiology. Euro J
Clin Nutr 2009;63:1377–86.
8. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol
2008;3:1535–41.
9. Hossein-nezhad A, Holick MF. Vitamin D for health: a global
perspective. Mayo Clin Proc 2013;88:720–55.
10. Mitri J, Muraru M, Pittas A. Vitamin D and type 2 diabetes:
a systematic review. Eur J Clin Nutr 2011;65:1005–15.
11. Soares MJ, Pathak K, Calton EK. Calcium and vitamin d in the
regulation of energy balance: where do we stand? Int J Mol Sci
2014;15:4938–45.
12. Lai YH, Fang TC. The pleiotropic effect of Vitamin D. ISRN Nephrol
2013;2013:898125.
13. Calton E, Keane K, Soares M. The potential regulatory role of
vitamin D in the bioenergetics of inflammation. Cur Opin Clin Nutr
Metab Care 2015;18:367–73.
14. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune
system: vitamins A and D take centre stage. Nat Rev Immunol
2008;8:685–98.
15. Alyami A, Soares M, Sherriff J, et al. Vitamin D & endothelial
function. Indian J Med Res 2014;140:483–90.
16. Dalan R, Liew H, Tan WKA, et al. Vitamin D and the endothelium:
basic, translational and clinical research updates. IJC Metab Endocr
2014;4:4–17.
17. Merke J, Milde P, Lewicka S, et al. Identification and regulation of
1, 25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,
25-dihydroxyvitamin D3. Studies in cultured bovine aortic
endothelial cells and human dermal capillaries. J Clin Invest 1989;
83:1903–15.
18. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1,
25-dihydroxyvitamin D3 by human endothelial cells is regulated by
inflammatory cytokines: a novel autocrine determinant of vascular
cell adhesion. J Am Soc Nephrol 2002;13:621–9.
19. Goodfellow J, Owens D, Henderson A. Cardiovascular syndromes
X, endothelial dysfunction and insulin resistance. Diabetes Res Clin
Pract 1996;31:S163–71.
20. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships
between insulin resistance and endothelial dysfunction: molecular
and pathophysiological mechanisms. Circulation
2006;113:1888–904.
21. Yaginuma T, Avolio A, O’Rouke M, et al. Effect of glyceryl trinitrate
on peripheral arteries alters left ventricular hydraulic load in man.
Cardiovasc Res 1986;20:153–60.
22. Woodman RJ, Watts GF. Measurement and application of arterial
stiffness in clinical research: focus on new methodologies and
diabetes mellitus. Med Sci Monit 2003;9:RA81–9.
23. Woodman RJ, Watts GF, Kingwell BA, et al. Interpretation of the
digital volume pulse; its relationship with large and small artery
compliance. Clin Sci 2003;104:283–5.
4 Alyami A, et al. BMJ Open 2015;5:e006835. doi:10.1136/bmjopen-2014-006835
Open Access
group.bmj.com on July 21, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
24. Barac A, Campia U, Panza JA. Methods for evaluating endothelial
function in humans. Hypertension 2007;49:748–60.
25. Ridker PM. Inflammatory biomarkers and risks of myocardial
infarction, stroke, diabetes, and total mortality: implications for
longevity. Nutr Rev 2007;65(Suppl 3):S253–9.
26. Witkowska AM. Soluble ICAM-1: a marker of vascular inflammation
and lifestyle. Cytokine 2005;31:127–34.
27. Chen N, Wan Z, Han SF, et al. Effect of vitamin D supplementation
on the level of circulating high-sensitivity C-reactive protein: a meta-
analysis of randomized controlled trials. Nutrients 2014;6:2206–16.
28. Beveridge LA, Struthers AD, Khan F, et al. Effect of vitamin D
supplementation on blood pressure: a systematic review and
meta-analysis incorporating individual patient data. JAMA Intern Med
2015;175:745–54.
29. Liu ZM, Woo J, Wu SH, et al. The role of vitamin D in blood pressure,
endothelial and renal function in postmenopausal women. Nutrients
2013;5:2590–610.
30. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement.
Ann Intern Med 2009;151:264–9.
31. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of
reports of randomized clinical trials: is blinding necessary? Control
Clin Trials 1996;17:1–12.
32. Centre for Evidence in Transplantation. Assessment of randomised
controlled trials (RCTs). 2010. http://www.transplantevidence.com/
library_rct.php (accessed 08–08–2014).
33. Hamilton L. Statistics with STATA: Version 12. USA: Cengage
Learning, 2012.
Alyami A, et al. BMJ Open 2015;5:e006835. doi:10.1136/bmjopen-2014-006835 5
Open Access
group.bmj.com on July 21, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
endothelial function
effect of vitamin D supplementation on 
A systematic review protocol examining the
A Alyami, MJ Soares, JL Sherriff, Y Zhao, J Hallett and F Coombes
doi: 10.1136/bmjopen-2014-006835
2015 5: BMJ Open 
 http://bmjopen.bmj.com/content/5/6/e006835




This article cites 31 articles, 8 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (285)Research methods
 (1085)Public health
 (174)Nutrition and metabolism




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 21, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
